We are live on
!
Find out more
WCA
Waypoint Capital Advisors Portfolio holdings
AUM
$470M
1-Year Est. Return
32.8%
This Fund
S&P 500
This Quarter
Est. Return
+5.89%
1 Year Est. Return
+32.8%
3 Year Est. Return
+50.26%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$320M
AUM Growth
+$13.4M
(+4.4%)
Cap. Flow
-$1.68M
Cap. Flow
% of AUM
-0.52%
Top 10 Holdings %
Top 10 Hldgs %
37.7%
Holding
136
New
3
Increased
60
Reduced
28
Closed
4
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Avantis International Equity ETF
AVDE
|
+$3.61M |
| 2 |
Avantis US Equity ETF
AVUS
|
+$2.65M |
| 3 |
Avantis Emerging Markets Equity ETF
AVEM
|
+$1.49M |
| 4 |
Avantis US Large Cap Value ETF
AVLV
|
+$1.34M |
| 5 |
Vanguard Morningstar Growth ETF
VUG
|
+$1.01M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
RXDX
Prometheus Biosciences, Inc. Common Stock
RXDX
|
+$16.6M |
| 2 |
Schwab US Dividend Equity ETF
SCHD
|
+$326K |
| 3 |
iShares Russell 3000 ETF
IWV
|
+$246K |
| 4 |
Target
TGT
|
+$227K |
| 5 |
C.H. Robinson
CHRW
|
+$193K |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 7.73% |
| 2 | Industrials | 6.04% |
| 3 | Healthcare | 5.7% |
| 4 | Consumer Discretionary | 3.03% |
| 5 | Consumer Staples | 2.54% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
126
McDonald's
MCD
$193B
| $231K | 0.07% |
773
+15
| +2% | +$4.36K |
|
127
iShares US Technology ETF
IYW
$22.6B
| $218K | 0.07% |
+2,000
| New | +$196K |
|
128
Comcast
CMCSA
$87.3B
| $212K | 0.07% |
5,113
-458
| -8% | -$18.2K |
|
129
Idexx Laboratories
IDXX
$44.9B
| $203K | 0.06% |
404
+4
| +1% | +$1.92K |
|
130
AquaBounty Technologies
AQB
$4.73M
| $121K | 0.04% |
17,000
| – | – |
|
131
Select Water Solutions
WTTR
$2.22B
| $112K | 0.03% |
13,822
| – | – |
|
|
ONCT
132
DELISTED
Oncternal Therapeutics, Inc. Common Stock
ONCT
| $13.4K | ﹤0.01% |
1,913
| – | – |
|
|
133
Schwab US Dividend Equity ETF
SCHD
$104B
| – | – |
-13,383
| Closed | -$326K |
|
134
PUT
State Street SPDR S&P 500 ETF Trust
SPY
$771B
| – | – |
-300
| Closed | -$123K |
|
|
135
Target
TGT
$66.3B
| – | – |
-1,371
| Closed | -$227K |
|
|
RXDX
136
DELISTED
Prometheus Biosciences, Inc. Common Stock
RXDX
| – | – |
-154,466
| Closed | -$16.6M |
|
Similar funds
SIGI
FPFS
VCMC
SFP
EDRIA
MRCM
AC
NIC
Waypoint Capital Advisors's Q2 2023 Portfolio in Review
As of Q2 2023, Waypoint Capital Advisors held 136 positions worth $320M, up 4.4% from $307M the previous quarter. Its ten largest holdings account for 38% of the portfolio.
Waypoint Capital Advisors's Q2 2023 filing shows 3 new, 60 increased, 28 reduced and 4 closed positions. Its largest new stake was TELA Bio: 40,000 shares worth $406K. The largest sale was Prometheus Biosciences, Inc. Common Stock, an estimated $16.6M.
By sector, the portfolio is most concentrated in Technology at 7.7% of assets, up from 6.8% a quarter earlier, followed by Industrials and Healthcare.
- Waypoint Capital Advisors's largest Q2 2023 buy was TELA Bio: 40,000 shares worth $406K.
- Waypoint Capital Advisors added most to Avantis International Equity ETF in Q2 2023, an estimated $3.61M increase.
- Waypoint Capital Advisors's biggest Q2 2023 reduction was iShares Russell 3000 ETF, cutting an estimated $246K.
- Waypoint Capital Advisors fully exited Prometheus Biosciences, Inc. Common Stock in Q2 2023, selling an estimated $16.6M.
- Waypoint Capital Advisors's ten largest holdings make up 38% of its $320M portfolio in Q2 2023.
- Waypoint Capital Advisors opened 3 new positions and closed 4 in Q2 2023.
- Waypoint Capital Advisors's portfolio value rose 4.4% quarter-over-quarter to $320M.
Based on Waypoint Capital Advisors's 13F filing for Q2 2023, filed 13 Jul 2023.